Similar articles

• Toxic epidermal necrolysis following treatment with oxaprozin.

  Carucci JA, Cohen DE. Carucci JA, et al. Int J Dermatol. 1999 Mar;38(3):233-4. doi: 10.1046/j.1365-4362.1999.00590.x. Int J Dermatol. 1999. PMID: 10208628 No abstract available.
• Oxaprozin. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

  Todd PA, Brogden RN. Todd PA, et al. Drugs. 1986 Oct;32(4):291-312. doi: 10.2165/00003495-198632040-00001. Drugs. 1986. PMID: 3536423 Review.
• Double-blind study on the interaction of oxaprozin with metoprolol in hypertensives.

  Halabi A, Linde M, Zeidler H, König J, Kirch W. Halabi A, et al. Cardiovasc Drugs Ther. 1989 Jun;3(3):441-3. doi: 10.1007/BF01858116. Cardiovasc Drugs Ther. 1989. PMID: 2487540 Clinical Trial. No abstract available.
• Pharmacokinetics of oxaprozin in women receiving conjugated estrogen.

  Scavone JM, Ochs HR, Greenblatt DJ, Matlis R. Scavone JM, et al. Eur J Clin Pharmacol. 1988;35(1):105-8. doi: 10.1007/BF00555518. Eur J Clin Pharmacol. 1988. PMID: 3220091
• Clinical pharmacokinetics of oxaprozin.

  Davies NM. Davies NM. Clin Pharmacokinet. 1998 Dec;35(6):425-36. doi: 10.2165/00003088-199835060-00002. Clin Pharmacokinet. 1998. PMID: 9884815 Review.